Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: Characterizing a Northeast Brazilian Population

被引：35

作者：

Felix G.E.S. ^{[1
,2
]}

Abe-Sandes C. ^{[1
]}

Machado-Lopes T.M.B. ^{[1
]}

Bomfim T.F. ^{[1
]}

Guindalini R.S.C. ^{[1
,3
]}

Santos V.C.S.A.R. ^{[1
]}

Meyer L. ^{[1
]}

Oliveira P.C. ^{[1
,2
]}

Neiva J.C. ^{[1
]}

Meyer R. ^{[1
]}

Romeo M. ^{[1
]}

Toralles M.B. ^{[1
]}

Nascimento I. ^{[1
]}

Abe-Sandes K. ^{[1
,2
]}

机构：

[1] Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador

[2] Laboratório Avançado de Saúde Pública, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador

[3] Departamento de Radiologia e Oncologia, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo

来源：

Human Genome Variation | / 1卷 / 1期

关键词：

D O I：

10.1038/hgv.2014.12

中图分类号：

学科分类号：

摘要：

Considering the importance of BRCA1, BRCA2, CHEK2 and TP53 in the development of hereditary early-onset breast and ovarian cancer and that the genetic susceptibility profile of the Northeast population from Brazil has never been analyzed, this study aimed to verify the frequency of mutations of clinical significance in these genes in high-risk hereditary breast and ovarian cancer (HBOC) syndrome patients from that region. DNA samples from 106 high-risk unrelated patients mostly from Bahia, the biggest state in the Northeast region, were analyzed. These patients underwent full BRCA1 gene sequencing, screening for common founder mutations in the BRCA2, CHEK2 and TP53 genes and genetic ancestry analysis with nine ancestry informative markers. The positive results were confirmed by two sequencing reactions. Three mutations of clinical significance were found: BRCA1 p.R71G (4.71%), 3450del4 (3.77%) and TP53 p.R337H (0.94%). The genetic ancestry analysis showed a high European ancestry contribution (62.2%) as well as considerable African (31.2%) and Amerindian (6.6%) ancestry contributions (r2 = 0.991); this degree of heterogeneity was also significant in the population structure analysis (r = 0.604). This population is highly admixed with a different spectrum of genetic susceptibility, with the Galician founder mutation BRCA1 p.R71G accounting for 50% of all identified mutations in high-risk HBOC patients. TP53 p.R337H was also significantly frequent; thus, the combined screening of BRCA1/2 and TP53 should be offered to high-risk HBOC patients from Northeast Brazil. © 2014 The Japan Society of Human Genetics All rights reserved.

引用

共 59 条

[1]

Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., Global Cancer Statistics, CA Cancer J Clin, 61, pp. 69-90, (2011)

[2]

Smith E.C., An overview of hereditary breast and ovarian cancer syndrome, J Midwifery Womens Health, 57, pp. 577-584, (2012)

[3]

Apoustolou P., Fostira F., Hereditary breast cancer: The era of new susceptibility genes, Biomed Res Int, 2013, (2013)

[4]

Achatz M.I.W., Olivier M., Le Calvez F., Martel-Planche G., Lopes A., Rossi B.M., Et al., The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families, Cancer Lett, 245, pp. 96-102, (2007)

[5]

Allinen M.M., Huusko P., Mantyniemi S., Launonen V., Winqvist R., Mutation analysis of the CHEK2 gene in families with hereditary breast cancer, Br J Cancer, 85, pp. 209-212, (2001)

[6]

Walsh T., Casadei S., Coats K.H., Swisher E., Stray S.M., Higgins J., Et al., Spectrum of mutations in BRCA1, BRCA2, CHEK2, e TP53 in families at high risk of breast cancer, J Am Med Assoc, 295, pp. 1378-1388, (2006)

[7]

Bordeleau L., Panchal S., Goodwin P., Prognosis of BRCA-associated breast cancer: A summary of evidence, Breast Cancer Res Treat, 119, pp. 13-24, (2010)

[8]

Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., Et al., The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Eng J Med, 336, pp. 1401-1408, (1997)

[9]

Machado P.M., Brandao R.D., Cavaco B.M., Eugenio J., Bento S., Nave M., Et al., Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: Evidence for a founder effect and analysis of the associated phenotypes, J Clin Oncol, 25, pp. 2027-2034, (2007)

[10]

Peixoto A., Santos C., Rocha P., Pinheiro M., Principe S., Pereira D., Et al., The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal, Breast Cancer Res Treat, 114, pp. 31-38, (2009)

← 1 2 3 4 5 6 →